시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전이성 폐 선암 치료 시장 보고서(2025년)
Metastatic Lung Adenocarcinoma Treatment Global Market Report 2025
상품코드 : 1760634
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,632,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,586,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,540,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전이성 폐 선암 치료 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 흡연 및 환경 요인의 증가, 새로운 약물 치료법의 승인 증가, 신흥 시장의 의료 인프라 확대, 개인 맞춤형 의학 접근법의 증가, 제약 회사와 연구 기관 간의 협력 확대에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 액체 생검 기술의 발전, 더 나은 결과를 위한 첨단 복합 치료법 개발, 표적 약물 전달 시스템의 혁신, 정밀 치료를 위한 AI 기반 진단 기술의 발전, 면역 종양학 치료의 발전 등이 있습니다.

표적 치료의 채택이 증가함에 따라 전이성 폐 선암 치료 시장이 성장할 것으로 예상됩니다. 표적 치료는 종양의 발생과 확산을 촉진하는 특정 유전자 또는 단백질을 표적으로 하는 약물을 사용하여 암의 성장을 차단합니다. 이 접근법은 특정 유전자 변이를 표적으로 하기 때문에 정밀성이 뛰어나고, 기존 치료법에 비해 부작용이 적고 치료 효과가 더 뛰어나기 때문에 인기를 얻고 있습니다. 전이성 폐 선암의 경우, 표적 치료는 암 성장에 기여하는 유전적 변이를 차단하여 환자의 생존율과 삶의 질을 개선하는 데 초점을 맞추고 있습니다. 예를 들어, 2023년 7월 미국 유전자 및 세포 치료학회(ASGCT)와 Citeline은 2023년 2분기 말까지 제2상 임상 시험에 진입한 유전자 치료제의 수가 5% 증가해 260개를 기록했다고 보고했습니다. 표적 치료법의 사용 증가가 시장 확대에 기여하고 있습니다.

전이성 폐 선암 치료 시장 기업들은 특정 유전적 변이를 표적화해 장기 생존율과 환자 예후를 개선하기 위해 화학요법 없는 치료법 개발에 집중하고 있습니다. 화학요법 없는 옵션인 표적 치료와 면역 요법은 전통적 화학요법의 심각한 부작용을 줄이면서 암을 효과적으로 관리하는 것을 목표로 합니다. 예를 들어, 2024년 8월 존슨앤드존슨은 미국 식품의약국(FDA)이 특정 EGFR 변이를 가진 전이성 비소세포폐암(NSCLC)에 대한 첫 번째 화학요법 없는 치료제로 RYBREVANT(amivantamab-vmjw)와 LAZCLUZE(lazertinib)의 병용 요법을 승인했다고 발표했습니다. 이 승인은 Phase 3 MARIPOSA 연구 결과를 기반으로 하며, 이 연구에서는 오시머티닙 대비 무진행 생존 기간이 개선된 것으로 나타났습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Metastatic lung adenocarcinoma treatment involves medical strategies aimed at managing lung cancer that has spread beyond the lungs. The primary goals are to slow tumor progression, alleviate symptoms, and prolong survival. As a palliative approach, it focuses on improving the quality of life while controlling the advancement of the disease.

The main types of treatment for metastatic lung adenocarcinoma are chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells throughout the body. It is often administered intravenously or orally and can be used alone or in combination with other treatments. The primary routes of administration are oral and intravenous, and the treatment is provided by various end-users, including hospitals, cancer research centers, and specialty clinics.

The metastatic lung adenocarcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides metastatic lung adenocarcinoma treatment market statistics, including the metastatic lung adenocarcinoma treatment industry global market size, regional shares, competitors with the metastatic lung adenocarcinoma treatment market share, detailed metastatic lung adenocarcinoma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic lung adenocarcinoma treatment industry. This metastatic lung adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic lung adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from$4.13 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the increasing incidence of lung cancer, the rising demand for targeted therapies, the growing adoption of immunotherapy, higher investments in oncology research, and the increasing awareness about early detection and diagnosis.

The metastatic lung adenocarcinoma treatment market size is expected to see strong growth in the next few years. It will grow to$6.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period can be attributed to the rising prevalence of smoking and environmental factors, the increasing approval of novel drug therapies, the expanding healthcare infrastructure in emerging markets, the rise in personalized medicine approaches, and the growing collaborations between pharmaceutical companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of advanced combination therapies for better outcomes, innovations in targeted drug delivery systems, progress in AI-driven diagnostics for precision treatment, and the advancement of immuno-oncology treatments.

The increasing adoption of targeted therapy is expected to drive the growth of the metastatic lung adenocarcinoma treatment market. Targeted therapy uses drugs to block cancer growth by targeting specific genes or proteins that drive tumor development and spread. This approach is gaining popularity due to its precision, as it targets specific genetic mutations, resulting in more effective treatment outcomes with fewer side effects compared to traditional therapies. For metastatic lung adenocarcinoma, targeted therapy focuses on blocking genetic mutations that fuel cancer growth, improving survival and quality of life for patients. For instance, in July 2023, the American Society of Gene and Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II trials increased by 5%, reaching 260 by the end of Q2 2023. The growing use of targeted therapies is contributing to the market's expansion.

Companies in the metastatic lung adenocarcinoma treatment market are also focusing on developing chemotherapy-free treatments that target specific genetic mutations to improve long-term survival rates and patient outcomes. Chemotherapy-free options, such as targeted therapy and immunotherapy, aim to manage cancer effectively while reducing the harsh side effects of traditional chemotherapy. For example, in August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval was based on the Phase 3 MARIPOSA study, which showed improved progression-free survival compared to osimertinib.

In January 2024, Bristol Myers Squibb (BMS) acquired Mirati Therapeutics for $4.8 billion to strengthen its cancer treatment portfolio, particularly its targeted therapies for non-small cell lung cancer (NSCLC). The acquisition supports BMS's strategy to expand its oncology pipeline and address unmet needs in cancer care. Mirati Therapeutics specializes in treatments for KRASG12C-mutated NSCLC, a critical mutation that is difficult to treat. This acquisition enhances BMS's ability to offer more precise, targeted treatments for lung cancer patients, further propelling the growth of the metastatic lung adenocarcinoma treatment market.

Major players in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, and Blueprint Medicines Corporation.

North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic lung adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic lung adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic lung adenocarcinoma treatment market consists of revenues earned by entities by providing services such as palliative and supportive care services, medical oncology services, diagnostic imaging, multidisciplinary team coordination, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic lung adenocarcinoma treatment market also includes sales of tumor-targeted radiopharmaceuticals, anti-angiogenic agents, and bispecific antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Lung Adenocarcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic lung adenocarcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metastatic lung adenocarcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic lung adenocarcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Metastatic Lung Adenocarcinoma Treatment Market Characteristics

3. Metastatic Lung Adenocarcinoma Treatment Market Trends And Strategies

4. Metastatic Lung Adenocarcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Lung Adenocarcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Metastatic Lung Adenocarcinoma Treatment Market Segmentation

7. Metastatic Lung Adenocarcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Metastatic Lung Adenocarcinoma Treatment Market

9. China Metastatic Lung Adenocarcinoma Treatment Market

10. India Metastatic Lung Adenocarcinoma Treatment Market

11. Japan Metastatic Lung Adenocarcinoma Treatment Market

12. Australia Metastatic Lung Adenocarcinoma Treatment Market

13. Indonesia Metastatic Lung Adenocarcinoma Treatment Market

14. South Korea Metastatic Lung Adenocarcinoma Treatment Market

15. Western Europe Metastatic Lung Adenocarcinoma Treatment Market

16. UK Metastatic Lung Adenocarcinoma Treatment Market

17. Germany Metastatic Lung Adenocarcinoma Treatment Market

18. France Metastatic Lung Adenocarcinoma Treatment Market

19. Italy Metastatic Lung Adenocarcinoma Treatment Market

20. Spain Metastatic Lung Adenocarcinoma Treatment Market

21. Eastern Europe Metastatic Lung Adenocarcinoma Treatment Market

22. Russia Metastatic Lung Adenocarcinoma Treatment Market

23. North America Metastatic Lung Adenocarcinoma Treatment Market

24. USA Metastatic Lung Adenocarcinoma Treatment Market

25. Canada Metastatic Lung Adenocarcinoma Treatment Market

26. South America Metastatic Lung Adenocarcinoma Treatment Market

27. Brazil Metastatic Lung Adenocarcinoma Treatment Market

28. Middle East Metastatic Lung Adenocarcinoma Treatment Market

29. Africa Metastatic Lung Adenocarcinoma Treatment Market

30. Metastatic Lung Adenocarcinoma Treatment Market Competitive Landscape And Company Profiles

31. Metastatic Lung Adenocarcinoma Treatment Market Other Major And Innovative Companies

32. Global Metastatic Lung Adenocarcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Lung Adenocarcinoma Treatment Market

34. Recent Developments In The Metastatic Lung Adenocarcinoma Treatment Market

35. Metastatic Lung Adenocarcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기